Biotech Innovator Oncolix Utilizing Novel Treatment to End Women's Cancers

Oncolix CEO Michael Redman tells TheStreet how his firm is extending lives by developing treatment for women's cancers. Here's what their biotech innovation has coming down the pipeline.
Publish date:

Oncolix Inc. (AEPP) wants to help women live longer. 

To help accomplish that mission, the biotech firm is developing novel drugs aimed at eradicating women's cancers such as ovarian and breast cancer.

From the sidelines of the LD Micro conference in Los Angeles, Oncolix CEO Michael Redman tells TheStreet about his company's approach to developing effective treatments using revolutionary scientific research.

For more from the LD Micro Conference in La:

TheStreet at LD Micro: What CEO Dave Callaway Sees in Small Caps This Year

STK Owner The ONE Group Is Carving Its Own Unique Space in the Dining Experience

SRAX Chief Weighs in as Company Readies for Cryptocurrency Dividend

Snap Interactive's New Blockchain App Could Flip Video Chat on Its Head

Micro Caps Take the Spotlight at LD Micro Conference - Here's What to Expect

Lexaria Biosciences Is Ready for the Legal Cannabis Boom

Here's How Small Cap Scissor Company Acme United Is Benefitting From Amazon

Here's How Cloud Computing Firm Fusion Is Using M&A to Get Ahead

Amazing Energy Isn't Afraid to Take on Big Oil